Helena Rodbard from Endocrine & Metabolic Consultants: Studying Canagliflozin as a Potential Treatment for Type 1 Diabetes Patients

While it is not yet approved for the treatment of patients with type 1 diabetes recent studies on canagliflozin have shown it could be an option for this patient population.

Helena W. Rodbard, MD, of Endocrine & Metabolic Consultants in Maryland and a past president of the American College of Endocrinology and the American Association of Clinical Endocrinologists discussed this research during the American Diabetes Association's annual meeting in New Orleans. While the medication is available for patients with type 2 diabetes already Rodbard said the results of this study showed benefits for the other form of diabetes as well.